■ MATERIAL WEAKNESS WATCH
Nasdaq · CIK 0001806952

LYEL Lyell Immunopharma, Inc.

B
80 / 100
Material weaknesses
1
Restatements
0
Auditor changes
0
Late filings
0
Quarters with open weakness
1
Remediations
0
Deductions
20
Remediation credit
0

Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.

Disclosures, in the company's words

  • Material weakness10-Q · filed 2026-11-04 · Item 1Asource filing ↗
    “We and our independent auditors have previously identified a material weakness in our internal control over financial reporting, and we cannot assure you that we will not identify other material weaknesses in the future.”

Filings read

Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.